(資料圖片)
招銀證券8月2日發(fā)布公告。Maintain BUY. We are positive about the FDA/EMA approvals of fruquintinib in late2023. We revised our TP from HK$37.49to HK$35.67based on DCF valuation (WACC:10.25%, terminal growth rate:3.0%).
(資料圖片)
招銀證券8月2日發(fā)布公告。Maintain BUY. We are positive about the FDA/EMA approvals of fruquintinib in late2023. We revised our TP from HK$37.49to HK$35.67based on DCF valuation (WACC:10.25%, terminal growth rate:3.0%).
m.w941.com 所刊載內容之知識產權為界限網(wǎng)絡及/或相關權利人專屬所有或持有。未經許可，禁止進行轉載、摘編、復制及建立鏡像等任何使用。
京ICP備2022022245號-30 Copyright 經濟導報網(wǎng) All Rights Reserved 版權所有 復制必究
違法和不良信息舉報 聯(lián)系郵箱：43 52 26 40 @qq.com
營業(yè)執(zhí)照公示信息